Cyclophosphamide (Cyclophosphamide) Patent Expiration, LOE Window & CMS Spending
Cyclophosphamide (Cyclophosphamide) by Hikma Pharmaceuticals: FDA Orange Book LOE 2036-02-15, 5 AB generics, $11.8M 2024 CMS Part D & Medicaid spend, and $3,500 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Hikma Pharmaceuticals |
| FDA Application & Pathway | N203856 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2036-02-15 |
| Orange Book Patents (*PED Extensions) | 3 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 5 |
| 2024 CMS Total Public Spend | $11.8M |
| 2024 Medicare Part D Spend | $2.1M |
| 2024 Medicaid Spend | $9.7M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($3,500 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Hikma Pharmaceuticals across sibling Meru public-data platforms.